OSLO, NORWAY--(Marketwired - May 15, 2013) -
Algeta ASA (
New dates are as follows:
2(nd) Quarter Results 2013: 28 August 2013
3(rd) Quarter Results 2013: 6 November 2013
All dates are tentative and could be subject to change.
Algeta is a company focused on developing novel targeted therapies forpatientswith cancer based on its alpha-pharmaceutical platform. TheCompany isheadquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,based inCambridge, MA performing commercial marketing operations in the US.Algeta islisted on the Oslo Stock Exchange (ALGETA.OL). For more informationpleasevisit www.algeta.com.
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
- Investment & Company Information
Communications & Corporate Affairs
+47 2202 4510
Citigate Dewe Rogerson
+44 207 638 9571
Gambit Hill & Knowlton
+47 22 04 82 00
MacDougall Biomedical Communications
+1 781 235 3060
US investor enquiries:
The Trout Group
+1 646 378 2953